Cutaneous T-Cell Lymphoma clinical trials at UC Irvine
1 in progress, 0 open to eligible people
Showing trials for
Mogamulizumab Q4week Dosing in Participants With R/R CTCL
Sorry, in progress, not accepting new patients
This is an open-label, multicenter, Phase 2 study to evaluate the safety and tolerability of mogamulizumab given Q4W following initial weekly induction in adult participants with relapsed/refractory MF and SS subtypes of CTCL. The study is composed of a 28-day Screening Period during which participants are screened for entry into this study, followed by a treatment period of up to 2 years from Cycle 1 Day 1.
Irvine, California and other locations